Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-788 in Non-Small Cell Lung Cancer
NCT02716116Phase 2Completed
- Sponsor
- Takeda
- Start
- Jun 2016
- Primary completion
- Sep 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 10
01
Overview
A Phase 2 trial of mobocertinib in non-small cell lung cancer (NSCLC), solid tumor, sponsored by Takeda. Started Jun 2016; status: completed.
02
Drugs
mobocertinib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT02716116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02716116.